Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations
about
Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trialsManagement of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Sulphonylurea monotherapy for patients with type 2 diabetes mellitusSulphonylurea monotherapy for patients with type 2 diabetes mellitusState Medicaid programs did not make use of prior authorization to promote safer prescribing after rosiglitazone warningStandards of medical care in diabetes--2012Clinically and pharmacologically relevant interactions of antidiabetic drugsPolypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 DiabetesThe risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studiesDiabetic kidney disease: from physiology to therapeuticsOptimal management of type 2 diabetes in patients with increased risk of hypoglycemiaA Novel TGR5 Activator WB403 Promotes GLP-1 Secretion and Preserves Pancreatic β-Cells in Type 2 Diabetic MiceUpdate on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association.Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the DiseaseAvoiding weight gain in cardiometabolic disease: a systematic reviewTherapeutic trial of metformin and bortezomib in a mouse model of tuberous sclerosis complex (TSC)Metformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer CellsConsensus report: the current role of self-monitoring of blood glucose in non-insulin-treated type 2 diabetesStandards of medical care in diabetes--2013Bridging Type 2 Diabetes and Alzheimer's Disease: Assembling the Puzzle Pieces in the Quest for the Molecules With Therapeutic and Preventive Potential2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implicationsEvaluation of patient-reported outcomes data in structured diabetes education intervention: 2-year follow-up data of patient empowerment programme.Precision diabetes: learning from monogenic diabetes.Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)Identification of genetic variants in pharmacogenetic genes associated with type 2 diabetes in a Mexican-Mestizo populationComparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: A meta-analysis.B lymphocytes in human subcutaneous adipose crown-like structuresSevere hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial dataEmerging gliptins for type 2 diabetes.Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus.Results from a dietary survey in an Indian T2DM population: a STARCH study.Efficacy and safety of saxagliptin as add-on therapy in type 2 diabetes.Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort studyEfficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.Effects of Teraphy with Basal Insulin Analogues Combined with GLP 1 Analogues and Metformin in the Treatment of Obese Patients with Poorly Regulated Postprandial Glycemia.Personalizing guidelines for diabetes management: twilight or dawn of the expert?Comparative efficacy of glimepiride and metformin in monotherapy of type 2 diabetes mellitus: meta-analysis of randomized controlled trialsMetformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosis
P2860
Q21144611-64EBE71E-56B1-4F32-A0B2-0C63BC0E2B32Q22241288-51AA2683-98EC-4F95-9A6C-7E63AD163F35Q24186660-0C8C6327-F3A4-425A-913F-F583231F15D0Q24197884-26B5387D-69D5-4328-81EF-A9EA2E56371EQ24604853-8D4A5BFF-901E-4EE9-A6F4-D46091EC9F59Q24632533-4CCED567-4A2B-47AA-9CCF-CEAEB19A6B42Q26752468-DBF354E8-07D8-4AFC-A32B-61E5E69625EDQ26767283-F137E704-FE13-4C28-81A5-707022A8C67BQ26999933-4C552FB2-82FA-4B64-8DA6-AA562E029D4FQ27021392-3D5C95CA-5692-4593-8AFA-E208388E1AC0Q27026847-A425FBEF-17AD-41F4-982A-BBF78BCC8958Q27301757-69B2C0FA-8695-47F6-BFD5-1CA123D8A71CQ27687851-F049756A-0481-4A79-8A63-CAAC21FE0050Q28069065-0006D1E6-CA5F-4400-98BD-95228C9C422FQ28081926-6AE4C694-BFF2-44E0-8F21-7458D9A1E94BQ28481010-AF60DA91-CBB5-4FAA-8CED-FADAAF2BF121Q28547140-89DB40DD-4F65-4FEF-A3AA-0B9C2BB78B8BQ28732681-1466D2D9-0EAC-4E01-A951-BD12410E8F17Q29620309-B7565C17-633D-4266-A7D5-724AEEB30845Q29994589-02328BF4-9C3D-4763-81D1-39FC5730FEF5Q30239808-5AD416FF-F591-46D2-850F-E8B521BDBAD9Q31130301-987DEC2B-4F17-40F8-9241-7236E0DA97EEQ33453490-BFB2ADEA-399D-40B0-A05C-E53804A9190BQ33556240-BBE6E8C5-C32D-4099-ADEC-DE9400B8D25CQ33696974-C9042B86-3608-4E8F-82B0-BABA45FECC0FQ33812170-5F11FB99-DC33-4F25-8845-55FA4C07A2D7Q33858377-FC066D8D-5692-499E-BEBF-1EDDDAF36EC7Q33871397-B70F578A-047F-4C56-8C4F-0A02BE754602Q34186722-264F2A58-831C-4686-94DB-0BE19C5814FDQ34286013-FD420E31-1050-42F2-B27A-AAFACBBF1AEDQ34347884-B0412EF7-9F5F-4369-BE2F-E3BDB68AFA9CQ34397646-AA4CDCD9-587C-4066-B483-CD720376C2A6Q34439045-E06827CA-7E63-4130-A95C-18B64F0CB777Q34454269-FF5F7E9E-DBC8-4F8A-A9D1-8B8260E67F8AQ34644993-FDEA5412-E39D-4BBC-84F5-2346A6017B63Q34646948-1EF5C3D3-4818-422C-99E7-508F9A34F842Q34725461-29958997-E304-4546-9522-F24736C28F9AQ34810165-9428EE0B-539A-4DF8-AD08-F93B419AFE21Q35042504-005074F9-05D5-4DBF-AFC8-44D38DEB6533Q35114963-62E65769-817F-43DA-A810-F53571918478
P2860
Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Comparative effectiveness and ...... drugs and 2-drug combinations
@ast
Comparative effectiveness and ...... drugs and 2-drug combinations
@en
Comparative effectiveness and ...... drugs and 2-drug combinations
@en-gb
Comparative effectiveness and ...... drugs and 2-drug combinations
@nl
type
label
Comparative effectiveness and ...... drugs and 2-drug combinations
@ast
Comparative effectiveness and ...... drugs and 2-drug combinations
@en
Comparative effectiveness and ...... drugs and 2-drug combinations
@en-gb
Comparative effectiveness and ...... drugs and 2-drug combinations
@nl
prefLabel
Comparative effectiveness and ...... drugs and 2-drug combinations
@ast
Comparative effectiveness and ...... drugs and 2-drug combinations
@en
Comparative effectiveness and ...... drugs and 2-drug combinations
@en-gb
Comparative effectiveness and ...... drugs and 2-drug combinations
@nl
P2093
P2860
P3181
P1476
Comparative effectiveness and ...... drugs and 2-drug combinations
@en
P2093
Eric B Bass
Jodi B Segal
Lauren Block
Lisa M Wilson
Milo A Puhan
Nisa M Maruthur
Padmini Ranasinghe
Ranee Chatterjee
Shari Bolen
Sonal Singh
P2860
P304
P3181
P356
10.7326/0003-4819-154-9-201105030-00336
P407
P577
2011-05-03T00:00:00Z